Purpose: Impella 5.0 is a short-term left ventricle assist device (LVAD), inserted retrograde into the left ventricle across the aortic valve through a surgical peripheral access. Impella has been utilized for various indications but in the setting of bridge-to-bridge application there are limited reports. Methods: We performed a retrospective observational analysis of Impella utilization at our institution as bridge to long-term LVADs. The primary end-point was survival during Impella support. Results: Between December 2010 and February 2012, we implanted 20 Impella in patients with cardiogenic shock and, among these, 5 were implanted as bridge to long-term LVADs. In this latter group, mean age at the time of implantation was 44 ± 15.6 ...
BACKGROUND: Little is known about safety and efficacy of the use of Impella 5.5 compared to previous...
Introduction: The Impella ventricular support system is a device that can be inserted percutaneously...
OBJECTIVE: We evaluated the acute and long-term results of the use of a new intracardiac microaxial ...
Impella LP 5.0 is a micro-axial, catheter-based left ventricle assist device (LVAD), which is insert...
Impella LP 5.0 is a micro-axial, catheter-based left ventricle assist device (LVAD), which is insert...
Background: Outcomes of traditional mechanical support paradigms (extracorporeal membrane oxygenatio...
The mainstay therapy for patients in critical cardiogenic shock (CS) is temporary mechanical circula...
Impella LP 5.0 is a microaxial left ventricular assist device (LVAD). The aim of our work was to ass...
BackgroundCardiogenic shock is associated with a high mortality rate. Mechanical circulatory support...
Patient DetailsA 52-year-old man with his first presentation in heart failure, NYHA class IV.Transth...
BACKGROUND: With the rapid development of mechanical circulatory support technologies, patients pres...
SummaryAimCardiogenic shock is associated with high mortality. We report our experience with the sho...
ABSTRACT: Venoarterial ECMO is a widely used treatment modality for patients with cardiogenic shock ...
We report the case of a 67-year-old male, with previous history of severe peripheral vascular diseas...
The use of mechanical circulatory support (MCS) to provide acute haemodynamic support for cardiogeni...
BACKGROUND: Little is known about safety and efficacy of the use of Impella 5.5 compared to previous...
Introduction: The Impella ventricular support system is a device that can be inserted percutaneously...
OBJECTIVE: We evaluated the acute and long-term results of the use of a new intracardiac microaxial ...
Impella LP 5.0 is a micro-axial, catheter-based left ventricle assist device (LVAD), which is insert...
Impella LP 5.0 is a micro-axial, catheter-based left ventricle assist device (LVAD), which is insert...
Background: Outcomes of traditional mechanical support paradigms (extracorporeal membrane oxygenatio...
The mainstay therapy for patients in critical cardiogenic shock (CS) is temporary mechanical circula...
Impella LP 5.0 is a microaxial left ventricular assist device (LVAD). The aim of our work was to ass...
BackgroundCardiogenic shock is associated with a high mortality rate. Mechanical circulatory support...
Patient DetailsA 52-year-old man with his first presentation in heart failure, NYHA class IV.Transth...
BACKGROUND: With the rapid development of mechanical circulatory support technologies, patients pres...
SummaryAimCardiogenic shock is associated with high mortality. We report our experience with the sho...
ABSTRACT: Venoarterial ECMO is a widely used treatment modality for patients with cardiogenic shock ...
We report the case of a 67-year-old male, with previous history of severe peripheral vascular diseas...
The use of mechanical circulatory support (MCS) to provide acute haemodynamic support for cardiogeni...
BACKGROUND: Little is known about safety and efficacy of the use of Impella 5.5 compared to previous...
Introduction: The Impella ventricular support system is a device that can be inserted percutaneously...
OBJECTIVE: We evaluated the acute and long-term results of the use of a new intracardiac microaxial ...